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Effector T cell differentiation requires the simulta-
neous integration of multiple, and sometimes oppos-
ing, cytokine signals. We demonstrated mTOR’s role
in dictating the outcome of T cell fate. mTOR-defi-
cient T cells displayed normal activation and IL-2
production upon initial stimulation. However, such
cells failed to differentiate into T helper 1 (Th1), Th2,
or Th17 effector cells. The inability to differentiate
was associated with decreased STAT transcription
factor activation and failure to upregulate lineage-
specific transcription factors. Under normally acti-
vating conditions, T cells lacking mTOR differentiated
into Foxp3+ regulatory T cells. This was associated
with hyperactive Smad3 activation in the absence of
exogenous TGF-b. Surprisingly, T cells selectively
deficient in TORC1 do not divert to a regulatory
T cell pathway, implicating both TORC1 and TORC2
in preventing the generation of regulatory T cells.
Overall, our studies suggest that mTOR kinase signal-
ing regulates decisions between effector and regula-
tory T cell lineage commitment.
INTRODUCTION
The fate of a naive T cell upon T cell receptor (TCR) engagement
is dictated by the environmental cues it receives from the inflam-
matory milieu. For example, cytokines within the inflammatory
microenvironment play a critical role in promoting specific
effector lineage commitment (Bettelli et al., 2007). Through the
activation of specific signal transducer and activator of transcrip-
tion (STAT) transcription factor pathways, lineage-specific tran-
scription factors are induced, fosteringdifferentiation intodistinct
effector lineages (Murphy and Reiner, 2002). Previously, such
fates were thought to be confined to T helper 1 (Th1) and Th2
cell lineage commitment (Weaver et al., 2006). Naive T cells acti-
vated in the presence of IFN-g and IL-12 developed into Th1
effector cells whereas T cells stimulated in the presence of IL-4
were fated to become Th2 effector cells.More recently, however,
it has also been shown that T cells stimulated in the presence of
IL-6 and TGF-b differentiate into an IL-17-producing effector
population termedTh17 cells. In addition, naive T cells stimulated832 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.in the presence of high concentrations of TGF-b are capable of
differentiating into Foxp3+ regulatory T cells (Chen et al., 2003).
In vitro, differentiation into these T cell subsets is easily achieved
through the precise addition of cytokines and cytokine-neutral-
izing antibodies. However, in vivo, T cells must integrate and
respond simultaneously to a broad array of diverse and even
opposing signals.
We have been studying the role of the mammalian target of
rapamycin (mTOR) as an important signaling molecule in trans-
lating environmental cues into specific types of T cell responses
(Powell, 2006). Specifically, inhibition of mTOR in Th1 effector
cells by rapamycin promotes T cell tolerance, even in the pres-
ence of costimulation (Zheng et al., 2007). In yeast and mamma-
lian cells, TOR integrates environmental cues, including amino
acid and nutrient availability, energy stores, and growth factor
signaling, and subsequently directs cell growth and proliferation
(HayandSonenberg, 2004). By analogy, in T cellswehypothesize
that mTOR integrates environmental cues and dictates the
outcome of antigen recognition. mTOR signaling proceeds via
two complexes: TOR Complex 1 (TORC1) and TORC2 (Guertin
et al., 2006). TORC1 contains Rheb (a small GTPase), the regula-
tory-associated protein of mTOR (raptor), G protein b-subunit-
like protein (GbL), the proline-rich Protein Kinase B (PKB)/Akt
substrate 40 kDa (PRAS40), and is rapamycin sensitive. TORC1
activation leads to the phosphorylation and activation of, among
other targets, the ribosomal S6 kinase (S6K1), and is thought to
be associatedwith ribosome biogenesis, autophagy, and protein
translation (Sabatini, 2006). TORC2 contains, in addition to
mTOR and GbL, the rapamycin-insensitive companion of mTOR
(rictor) and mammalian stress-activated protein kinase interact-
ing protein-1 (mSin1) (Guertin et al., 2006). Interestingly, even
thoughAkt activation is upstreamofmTOR signaling, the specific
phosphorylation of Akt at serine 473 is in fact a downstream
target of TORC2. Also, although it was initially thought that rapa-
mycin exclusively inhibited mTORC1 activation, it has become
clear that it can also inhibit TORC2 (Zeng et al., 2007).
In order to explore the potential role of mTOR in integrating
cytokine signaling and regulating T effector lineage commitment,
we generated mice in which mTOR is specifically deleted in
T cells. In this report we demonstrated that mTOR activation
was necessary for Th1, Th2, and Th17 effector T cell differentia-
tion, and even under fully activating conditions T cells lacking
mTOR differentiated into Foxp3+ regulatory T cells. Surprisingly,
by selectively deleting TORC1 activity in T cells, we are able to
demonstrateapreviouslyunappreciated role forTORC2signaling
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mTOR Regulates Effector T Cell Lineage CommitmentFigure 1. Phenotypic Analysis of Conditional mTOR-Deficient Mice
(A) PCR excision assay of cells from WT or T-Frap1/ mice. ‘‘In’’ refers to amplification of primers confirming the presence of the gene. ‘‘Out’’ refers to ampli-
fication of primers confirming excision of the gene.
(B) Immunoblot (IB) of mTOR in sorted populations. Raptor is included as a loading control.
(C) Flow cytometric analysis of thymocytes harvested from mice. Foxp3 versus CD25 is gated on CD4+ cells.
(D) Flow cytometric analysis of splenocytes. Foxp3 versus CD25 is gated on CD4+ cells. All data are representative of at least three independent experiments.in regulating Foxp3+ T cells. Thus our studies suggest that mTOR
kinase signaling regulatesdecisionsbetweeneffector and regula-
tory T cell lineage commitment.
RESULTS
Generation of mTOR-Deficient T Cells
Because mTOR null mice are early embryonic lethal, we sought
to conditionally delete the Frap1 gene in T cells (Frap1 is the
name of the gene that encodes mTOR protein). Mice carrying
a floxed Frap1 gene were crossed to mice harboring CD4-Cre
in order to delete the gene in double-positive (CD4+CD8+) and
CD4 and CD8 single-positive T lymphocytes. In this report,
Frap1fl/fl mice will be referred to as ‘‘wild-type,’’ whereas
Frap1fl/fl; CD4-Cre mice will be referred to as ‘‘T-Frap1/.’’ In
T-Frap1/ mice, the Frap1 gene was successfully deleted in
CD4+ and CD8+ cells (Figure 1A). As such, mTOR protein failed
to be expressed in CD4+ T cells (Figure 1B). The selective
expression of Cre recombinase in CD4+ T cell precursors was
supported by the fact that the Frap1 gene was present in non-
T cells (Figure 1A). In spite of the central role of mTOR in regu-lating cell growth and proliferation, the absence of mTOR had
a minimal effect on T cell development as determined by flow
cytometric analysis of thymocytes from WT and T-Frap1/
mice. In the thymus, there was a consistent increase in the
CD4:CD8 ratio in theT-Frap1/mice (3:1 versus 9:1) (Figure 1C).
However, the CD4:CD8 ratios in the spleen, peripheral blood,
and lymph nodes were similar and normal between the WT and
T-Frap1/ mice (Figure 1D, Figures S1–S3 available online).
B and T cell percentages were equivalent between the WT and
T-Frap1/ mice in peripheral blood and lymph nodes, but
a slight decrease in CD3+ cells was seen in the spleen (Figures
S1–S3). A role for Akt and mTOR in the development of regula-
tory T cells has been described (Haxhinasto et al., 2008; Sauer
et al., 2008). However, at baseline, deletion of mTOR did not alter
the development of ‘‘natural’’ CD4+CD25+Foxp3+ regulatory
T cells (Figures 1C and 1D). It is of note that in our model (which
employs CD4-Cre), mTOR is deleted during the double-positive
(DP) stage of T cell development. Thus our observations suggest
that deleting mTOR at this stage of T cell development does
not result in overt perturbations in CD4+, CD8+, and regulatory
T cells.Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc. 833
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mTOR Regulates Effector T Cell Lineage CommitmentFigure 2. Characterization of T Cell Function in mTOR-Deficient T Cells
(A) IB of phospho-S6K1 from CD4+ T cells stimulated with immobilized anti-CD3 (1 mg/mL) and anti-CD28 (2 mg/mL) for the indicated times.
(B) IB of phospho-Akt (T308), as in (A).
(C) IB of phospho-Akt (S473), as in (A).
(D) Activation markers, CD69 and CD25, upon stimulation. Cells were gated on CD4 after 24 hr of mock or anti-CD3 stimulation.
(E) IL-2 production from initial stimulation of mTOR-deficient T cells. Data are pooled from three independent experiments. Error bars indicate SD.
(F) Proliferation analysis of mTOR-deficient T cells by CFSE dilution. Plots are gated on CD4+ T cells. Gates indicate cells that have undergone at least one divi-
sion. All data are representative of at least three independent experiments.Normal TCR-Induced Activation and IL-2 Secretion
in the Absence of mTOR Signaling
mTOR signaling occurs via two complexes, TORC1 and TORC2.
To determine whether T cells from the T-Frap1/ mice lacked
TORC1 activity, T cells fromWT and T-Frap1/mice were stim-
ulated with anti-CD3 and anti-CD28 and S6K1 phosphorylation
was determined by immunoblot analysis (McMahon et al.,
2002). There was very little S6K1 phosphorylation in stimulated834 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.mTOR-deficient T cells, indicating a lack of TORC1 activity,
concomitant with mTOR deletion (Figure 2A). Akt activation is
an important upstream inducer of mTOR (Hay and Sonenberg,
2004). Phosphorylation of Akt on threonine 308 was slightly
enhancedabovewild-type amounts (Figure 2B). This observation
confirms that Akt activation upstream of mTOR is intact. Further-
more, the enhanced activation of Akt was consistent with the
absenceof aTORC1-mediatednegative feedback loop (Sabatini,
Immunity
mTOR Regulates Effector T Cell Lineage Commitment2006). To interrogate TORC2 activity, we measured Akt phos-
phorylation at serine 473, a known substrate of TORC2 signaling.
LikeS6K1, therewas very little TORC2-dependent Akt phosphor-
ylation in the mTOR-deficient T cells (Figure 2C). Thus we have
established that although TCR-induced signaling proximal to
mTOR is intact, the deletion of mTOR resulted in the inhibition
of both TORC1 and TORC2 activity.
We next wanted to determine the functional consequences of
TCR-induced signaling in T-Frap1/ T cells. Isolated CD4 cells
weremock stimulated or stimulated with anti-CD3 and irradiated
APCs overnight. Expression of CD69 (very early activation
antigen) and CD25 (IL-2Ra) was examined by flow cytometry.
Both WT and T-Frap1/ CD4+ cells upregulated activation
markers appropriately (Figure 2D). Concomitant with activation
markers, both WT and T-Frap1/ T cells produced equivalent
amounts of IL-2 upon anti-CD3 stimulation (Figure 2E). These
observations indicate that the TCR-induced signaling cascade
remains intact in mTOR-deficient T cells and that the ability of
naive T-Frap1/ T cells to initially become activated is not
affected by their lack of mTOR.
mTOR has been shown to play a role in promoting cell cycle
progression (Wiederrecht et al., 1995). To determine whether
the absence of mTOR affected proliferative responses, T cells
from WT and T-Frap1/ mice were labeled with CFSE, stimu-
lated with anti-CD3 and APCs, and evaluated by flow cytometry.
T cells from the T-Frap1/ mice proliferated less than CD4+
T cells from WT mice (Figure 2F). Consistent with this decrease
in proliferation is a failure to upregulate cyclin D3 (Figure S4).
However, proliferation of the CD4+ T cells from the T-Frap1/
mice was not abolished, indicating that mTOR is not strictly
necessary for proliferation (Colombetti et al., 2006). After 6 days
of activation, 49.0% of the T-Frap1/ cells proliferated com-
pared with 86.6% of the WT T cells. Furthermore, there is no
evidence of increased death in the activated mTOR-deficient
T cells as indicated by trypan blue exclusion (data not shown).
mTOR Is Necessary for Th1 and Th2 Effector T Cell
Differentiation
In light of the multiple inputs that dictate effector differentiation,
we hypothesized that mTOR might integrate these signals in
T cells and subsequently promote T cell lineage commitment.
T cells from WT and T-Frap1/ mice were activated under Th1
(in the presence of IFN-g, IL-12, and anti-IL-4) or Th2 (in the pres-
ence of IL-4 and anti-IFN-g) cell skewing conditions for 5 days
and then rechallenged with anti-CD3 and anti-CD28. Upon
rechallenge, WT T cells cultured in Th1 cell skewing conditions
produced IFN-g and failed to produce IL-4 (Figure 3A). Likewise,
the WT T cells cultured under Th2 cell skewing conditions
produced IL-4 upon rechallenge and failed to produce IFN-g
(Figure 3B). In contrast, T cells from T-Frap1/ mice failed to
differentiate into effector Th1 or Th2 cells, regardless of skewing
conditions. Thus, although naive T cells from the T-Frap1/mice
produce IL-2 at amounts similar to T cells from WT mice, in the
absence of mTOR, T cells fail to differentiate into effector cells
under skewing conditions in vitro.
Next we wanted to determine whether mTOR was required for
effector T cell differentiation in vivo by using Vaccinia virus,
a strong inducer of an antiviral Th1 response. To this end, we
bred our Frap1 floxed lines to mice carrying a transgenic T cellreceptor specific for HA peptide (clone 6.5). These HA-specific,
CFSE-labeled wild-type and mTOR-deficient CD4+ T cells were
adoptively transferred into B10.D2 host mice that were immu-
nized 1 day prior with Vaccinia virus expressing the HA antigen.
Five days after transfer, the mice were sacrificed and spleens
were harvested. The HA-specific donor T cells were then rechal-
lenged in vitro with high-dose peptide and APCs and examined
by intracellular cytokine staining (Figure 3C). Donor T cells from
host mice that were not immunized did not proliferate, nor did
they produce cytokines. Wild-type T cells from immunized
mice proliferated in vivo and produced copious amounts of
IFN-g upon rechallenge (Figures 3C and 3D). mTOR-deficient
T cells from immunized host mice did proliferate in response to
viral infection, albeit to a lesser degree. However, these cells
failed to produce IFN-g upon rechallenge. Importantly, this was
the case even for the mTOR-deficient T cells that underwent
several rounds of division. The fact that T cells lacking mTOR
went through multiple rounds of proliferation yet failed to
produce IFN-g indicates that the lack of Th1 cell differentiation
is not merely secondary to decreased proliferation. In addition,
upon rechallenge, the virally activated mTOR-deficient CD4+ T
cells produced much less IL-2 and TNF-a compared to T
cells from WT mice (Figures S5 and S6). Thus, in the absence
of mTOR, Vaccinia-specific T cells fail to differentiate into Th1
effector cells in vivo.
Cytokines promote lineage commitment in part by STAT
signaling that mediates subsequent upregulation of lineage-
specific transcription factors. Critical for effector T cell lineage
commitment is appropriate STAT activation in response to
specific cytokines. For example, Th1 cell differentiation is depen-
dent upon IL-12-induced STAT4 activation whereas Th2 cell
differentiation is promoted by IL-4-induced STAT6 activation.
Therefore, we wanted to determine whether mTOR played a role
in promoting STAT signaling. Previously activated WT and
mTOR-deficient T cells were stimulated with either IL-12 or IL-4
for 30 min and examined for STAT phosphorylation. IL-12-
induced phosphorylation of STAT4 was diminished in the
T-Frap1/ T cells (Figure 3E). Likewise, IL-4-induced STAT6
phosphorylation was decreased in the T-Frap1/ T cells. Of
note, both the IL-12 and IL-4 receptors were appropriately
expressed on T-Frap1/ T cells (data not shown). Thus, in
the absence of mTOR, the ability of cytokines to direct effector
lineage commitment ismitigated, in part, at the level of STAT acti-
vation.
Effector T cell lineage commitment is promoted by the upregu-
lation of lineage-specific transcription factors (Murphy and
Reiner, 2002). T-bet and GATA-3 play critical roles in promoting
Th1 and Th2 cell differentiation, respectively. We wanted to
determine whether mTOR was involved in regulating the expres-
sion of these transcription factors. Wild-type and mTOR-defi-
cient T cells were stimulated under Th1 and Th2 cell skewing
conditions and then interrogated for T-bet and GATA-3 expres-
sion by real-time PCR.Wild-type T cells demonstrated increased
T-bet expression in Th1 cells compared to Th2 cells. GATA-3
was expressed in wild-type Th2 but not Th1 cells (Figure 3F).
However, neither T-bet nor GATA-3 was upregulated in the
mTOR-deficient T cells under skewing conditions. These obser-
vations suggest that mTOR activation is required for the upregu-
lation of Th1 and Th2 lineage-specific transcription factors,Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc. 835
Immunity
mTOR Regulates Effector T Cell Lineage CommitmentFigure 3. mTOR-Deficient T Cells Fail to Differentiate into Th1 or Th2 Effector Cells
(A) IFN-g production wasmeasured by ELISA. Total lymphocytes were isolated frommice and stimulated with anti-CD3 in vitro and rested 5 days in the presence
of Th1 or Th2 cell skewing conditions. T cells were isolated by magnetic separation and then restimulated with anti-CD3 and anti-CD28 for 24 hr. Data are pooled
from three independent experiments and are represented as percent IFN-g activity relative to WT Th1 cells.
(B) As in (A), but for IL-4 (percentages are relative to WT Th2 cells).836 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.
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mTOR Regulates Effector T Cell Lineage CommitmentFigure 4. mTOR-Deficient T Cells Fail to Differentiate to Th17 Effector Cells
(A) Flow cytometric analysis of Th17 cells. T cells were activated in the presence or absence of Th17 cell skewing conditions and restimulated in vitro.
(B) Flow cytometric analysis of Peyer’s patch (PP) lymphocytes. PPs were isolated fromWT or T-Frap1/mice and stimulated with PMA and ionomycin for 5 hr.
(C) IL-21, RORgt, and IL-23R expression in nonbiasing or Th17 cell skewing conditions by real-time PCR analysis. Data are normalized to 18 s rRNA and scaled to
WT nonbiasing conditions. Error bars indicate SD.
(D) Previously activated T cells were stimulated with IL-6 (5 ng/mL) for 5 or 10 min and blotted for phospho-STAT3. All data are representative of at least three
independent experiments.consistent with decreased STAT4 and STAT6 activation noted
above.
mTOR Is Required for Th17 Effector Cell Lineage
Commitment
Having established that mTOR-deficient T cells fail to differen-
tiate into Th1 and Th2 effector T cells, we next wanted to deter-
minewhethermTORalsoplayeda role inpromotingTh17effector
cells. T cells from WT and T-Frap1/ mice were activated withanti-CD3 and cultured in IL-7 alone or TGF-b + IL-6 for 5 days,
restimulated, and examined by intracellular cytokine staining
for IL-17 production. Compared to WT cells cultured in media
alone,WT T cells cultured in IL-6 + TGF-b differentiated into Th17
cells (Figure 4A). Alternatively, the T cells from the T-Frap1/
mice failed to differentiate into Th17 cells under skewing condi-
tions. After our in vitro findings, we next examined whether
mTOR-deficient cells could differentiate to Th17 cells in vivo.
Th17 cells are found at relatively high frequencies in the gut(C) Proliferation and IFN-g production of donor cells was measured by intracellular cytokine staining 5 days after adoptive transfer. Production = mean fluores-
cence multiplied by the percent CFSElo.
(D) IFN-g production compiled from multiple mice as in (C). Data are representative of three independent experiments.
(E) Previously activated T cells were stimulated with IL-12 (5 ng/mL) or IL-4 (5 ng/mL) for 30 min and probed (IB) for phospho-STAT4 or STAT6, respectively.
(F) T-bet and GATA-3 expression from skewed Th1 or Th2 cells by real-time PCR. Values are normalized to 18 s rRNA levels and scaled to T-Frap1/ Th1 cell
conditions. Error bars indicate SD. Data are representative of five independent experiments.Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc. 837
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mTOR Regulates Effector T Cell Lineage Commitmentmucosa (Denning et al., 2007). Peyer’s patcheswere isolated and
stimulatedwithPMAand ionomycin to assay for IL-17production
by intracellular cytokine staining. Although 3.8% of the WT cells
are IL-17+, only 1.1% of cells from T-Frap1/ mice produced
IL-17 (Figure 4B). These data suggest thatmTORactivation plays
a role in Th17 cell lineage commitment in vivo.
Better characterization of the genetic program determining the
initial differentiation and subsequent expansion of Th17 cells has
been elucidated (Ivanov et al., 2007). Upon initial stimulation with
TGF-b and IL-6, T cells begin to express IL-21, which acts in an
autocrine fashion to potentiate the Th17 cell phenotype through
STAT3. This results in the expression of the retinoic-acid-related
orphan receptor g (RORgt), a transcription factor implicated in
the maintenance of the Th17 cell program. Th17 cells further
stabilize their phenotype by upregulating the IL-23R. To examine
whether there was a block in any of the steps of this process, we
stimulated mTOR-deficient T cells in Th17 cell-biasing condi-
tions and analyzed the expression of these genes by real-time
PCR. When cultured under IL-17 skewing conditions, T cells
from WT mice upregulated the expression of IL-21, IL-23R,
and RORgt. However, mTOR-deficient T cells failed to express
any of these genes above wild-type Th0 cell levels (Figure 4C).
Th17 cell lineage commitment is also dependent upon the acti-
vation of STAT3. Because T cells lackingmTOR failed to upregu-
late the STAT3-dependent genes IL-21 and RORgt, we sought to
determine whether STAT3 phosphorylation was intact in the
absence of mTOR. Previously activated T cells from WT and
T-Frap1/ mice were stimulated with IL-6 to induce STAT3
phosphorylation. Although wild-type T cells display a robust
increase in STAT3 phosphorylation at tyrosine 705, T cells lack-
ing mTOR fail to phosphorylate STAT3 (Figure 4D). Of note, the
IL-6 receptor is appropriately expressed on the T-Frap1/
T cells (data not shown). Thus, in the absence of mTOR, IL-6 fails
to activate STAT3 and consequently the genetic programs that
promote Th17 cell lineage commitment fail to be upregulated.
TCR Engagement in the Absence of mTOR Leads
to Regulatory T Cell Differentiation
T cells from T-Frap1/mice fail to differentiate into effector Th1,
Th2, and Th17 T cells both in vitro and in vivo. Nonetheless, naive
mTOR-deficient T cells respond initially to antigen by upregulat-
ing activation markers and producing IL-2 (Figure 2). Further-
more,mTOR-deficient T cells did not showevidence of increased
cell death (data not shown). Therefore, because the T-Frap1/
cells failed todifferentiate into knowneffector subsets,we sought
to determine the phenotype of these cells after antigen recogni-
tion, particularly if they were developing into regulatory T cells
(Treg cells). We activated WT and T-Frap1/ T cells with anti-
CD3 and APCs and analyzed the percentage of CD4+CD25+
Foxp3+ T cells 5 days later. Initially, the percentages of CD4+
CD25+Foxp3+ T cells in the WT and the T-Frap1/ mice were
equivalent at 5.92% and 6.07%, respectively (Figure 5A, top).
However, after stimulation, the percentage of CD4+CD25+
Foxp3+ T cells in the WT cultures was only 3.65% whereas the
percentage of CD25+Foxp3+ cells in the T-Frap1/ cultures
expanded to 19.0% (Figure 5A, bottom).
The phenotype and function of these Foxp3+ T cells derived
from T-Frap1/ mice were examined. The Foxp3+ T cells from
the T-Frap1/ mice expressed levels of Foxp3 similar to wild-838 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.type natural Treg cells as determined by mean fluorescence via
flow cytometry. Furthermore, the Foxp3+ T cells derived from
the T-Frap1/ mice expressed glucocorticoid-induced tumor
necrosis factor receptor (GITR) at similar levels as Foxp3+ cells
from wild-type mice (Figure S7). To determine the function of
these Foxp3+ cells, these cells were tested in an in vitro suppres-
sion assay. Expanded mTOR-deficient T cells were enriched for
CD25+ cells by magnetic separation and cocultured with CFSE-
labeled naive 6.5+ responder T cells, irradiated APCs, and their
cognate peptide. The responder cells receiving TCR stimulation
in the presence of the mTOR-deficient regulatory T cells demon-
strated decreased proliferation, indicating that the Foxp3+ T cells
from the mTOR-deficient cultures display potent suppressor
activity (Figure 5B).
Interestingly, although IL-2 clearly plays an important role in
activating T cells and enhancing T cell-mediated immunity, it
also plays an essential role in the induction of regulatory cells
(Lohr et al., 2006). BecausemTOR isdownstreamof IL-2 receptor
signaling, we wanted to examine the effect of IL-2 on regulatory
T cell generation in mTOR-deficient T cells. T cells from either
WT or T-Frap1/ mice were activated with anti-CD3 and APCs
and cultured in IL-7 alone or IL-7 + IL-2 for 5 days and then
examined by flow cytometry for CD4+CD25+Foxp3+ T cells. In
the absence of mTOR, a normally ‘‘activating’’ in vitro stimulation
led to the generation of 25.9% Foxp3+ regulatory T cells com-
pared to 1.72% inWTT cells (Figure 5C). Culture of theWTT cells
with IL-2 failed to increase the percentage of regulatory T cells
(0.76%). However, the addition of IL-2 to mTOR-deficient
T cells led to an expansion of Foxp3+ cells to 50.8%. These find-
ings suggest that the ability of IL-2 to promote regulatory T cell
differentiation is independent of IL-2-induced mTOR activation.
Thus, under normally activating conditions that would typically
induce Th1 cell responses in vitro, T cell activation in the absence
of mTOR signaling results in the generation of functional Foxp3+
regulatory T cells.
Onepossible explanation for our findings is thatmTORablation
causes the selective death of effector cells leading to an increase
in the percentage of regulatory T cells but not an increase in their
absolute numbers. For example, initially it was thought that
expression of cognate peptide in the thymus induced Treg
cell differentiation. Subsequently, it was shown that although
expression of peptide in the thymus led to an increase in the
percentage of Foxp3+ T cells, this increase was due to deletion
of CD4+ Foxp3 cells. That is, there was no increase in the abso-
lute number of Foxp3+ cells (Apostolou et al., 2002; van Santen
et al., 2004). To examine this possibility in our system, T cells
were harvested from WT and T-Frap1/ mice, labeled with
CFSE, and stimulated in vitro overnight. The cells were then res-
ted in IL-2 and IL-7 to promote Treg cell generation. The cultures
were examined daily for the total number of T cells as well as
CFSE dilution and Foxp3 expression. By day 6, we observed
that the WT T cells proliferated and had differentiated into
IFN-g-producing cells (Figure 5D). However, the T-Frap1/ cells
proliferated less and did not differentiate into IFN-g-producing
cells, and instead became Foxp3+ cells. Importantly, although
the absolute number of Foxp3+ T cells remained constant in the
wild-type cultures, T-Frap1/ cultures showed an increase in
the number of these cells (Figure 5E). The increase in absolute
numbers of regulatory T cells supports the notion that T cell
Immunity
mTOR Regulates Effector T Cell Lineage CommitmentFigure 5. mTOR-Deficient T Cells Differentiate Down a Regulatory Pathway
(A) Flow cytometric analysis of CD4+ T cells from WT or T-Frap1/ mice before stimulation and 5 days after stimulation.
(B) In vitro suppression assay with CD25+ fraction of mTOR-deficient T cells. Proliferation of responder cells was measured by CFSE dilution 72 hr after
stimulation.
(C) As in (A), but some cultures were supplemented with IL-2.
(D) T cells were isolated fromWT or T-Frap1/mice, CFSE labeled, and stimulated with anti-CD3 (107 per time point). Cultures were then supplementedwith IL-2
and IL-7. On day 2, 4, 6, and 8 after stimulation, cells were removed from culture, counted, and restimulated with anti-CD3 (5 mg/mL) and anti-CD28 (2 mg/mL),
then interrogated by flow cytometry for IFN-g production and Foxp3 expression. Plots are representative of day 6 cultures from this experiment. IFN-g+ gates
were drawn via unstimulated controls.
(E) Treg cell upregulation occurs in vitro because of an increase in Foxp3+ cells rather than death of effector cells. Data from (D) were compiled from three experi-
ments and absolute numbers were calculated. Error bars indicate SD.
(F) Adoptive transfers were performed as in Figure 3C. Donor cells were interrogated by differential Thy1 expression.
(G) WT B10.D2 host mice (Thy1.2+) were infected with Vac-HA and after 24 hr WT or T-Frap1/ 6.5+ T cells (Thy1.1 and Thy1.2) were adoptively transferred. One
day later, mice received a second transfer of 6.5+ CFSE-labeled naive WT responder T cells (Thy1.1+). Splenocytes were harvested and stimulated with peptide
and tested for cytokine production. Plots are gated on responders by Thy1.1 homozygosity.
(H) IFN-g production compiled from multiple mice as in (G). Data are representative of three independent experiments.
(I) Foxp3+ expression of the transferred WT and mTOR-deficient (Thy1.1 and Thy1.2 heterozygote) population from (G).Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc. 839
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mTOR Regulates Effector T Cell Lineage Commitmentactivation in the absence of mTOR promotes the generation of
such cells. In vitro, T cells stimulated in the absence of mTOR
signaling differentiate down a regulatory T cell pathway.
We then testedwhetherT-Frap1/cellswoulddifferentiate into
regulatory cells when activated by the strongly Th1 cell-polarizing
Vaccinia virus infection in vivo.Consistentwithour in vitro findings,
the response to Vaccinia virus in vivo also led to the development
of CD4+CD25+Foxp3+ regulatory T cells (Figure 5F). We next
tested the suppressive capabilities of mTOR-deficient T cells
that convert into Treg cells in vivo. Host B10.D2 (Thy1.2+) mice
were infected with Vaccinia-HA, and 1 day after infection either
wild-type or T-Frap1/CD4+ Thy1.1+ and Thy1.2+ (heterozygote)
T cells were adoptively transferred. One day later, CFSE-labeled
wild-type 6.5+ Thy1.1+ T cells were transferred and would be
examined as ‘‘responders.’’ Five days after transfer of responder
cells, splenocytes were challenged with high-dose HA peptide
and IFN-g production was examined by intracellular cytokine
staining. The T cells that were adoptively transferred along with
the naivemTOR-deficient T cells produced less IFN-g in response
toVaccinia infectionwhen compared to the responder cells adop-
tively transferred along with the naive WT cells (Figures 5G and
5H). Furthermore, when the transferred cells from T-Frap1/
were examined for regulatory T cell markers, a clear conversion
takes place (Figure 5I). This indicates that, in vivo, in response to
the strong Th1-inducing stimulus of Vaccinia infection, mTOR-
deficient T cells convert into regulatory T cells with potent
suppressive capabilities. The ability of the adoptively transferred
naive T-Frap1/ cells to suppress in vivo suggests that indeed
functional regulatory T cells are being generated. That is, in vivo
activation of T cells from T-Frap1/ mice by Vaccinia does not
lead merely to an increase in the percentage of regulatory cells
because of the selective death of effector cells, but rather to the
generation of regulatory T cells that functionally suppress.
mTOR-Deficient T Cells Are Hypersensitive to TGF-b
Because TGF-b is such a potent skewing agent of antigen-
induced regulatory T cells, one possible explanation for our find-
ingswas that cells fromT-Frap1/miceproducehigher amounts
of TGF-b. To examine this, splenocytes from WT or T-Frap1/
mice were cultured in media alone or stimulated with anti-CD3
overnight and examined for TGF-b production by ELISA. For
both theWT and T-Frap1/ cultures, there was a slight increase
in TGF-b expression upon activation (Figure 6A). However, the
amounts of TGF-b were equivalent, indicating that the develop-
ment of regulatory cells upon stimulation of the T-Frap1/
cultures is not the result of increased amounts of TGF-b.
Smad3 plays a critical role in promoting regulatory T cell differ-
entiation. TGF-b signaling activates Smad3, which, along with
TCR-induced NF-AT, contributes to the induction of Foxp3 by
promoting acetylation at the Foxp3 enhancer (Tone et al.,
2008). To examine Smad3 activation in mTOR-deficient T cells,
previously activated wild-type and T-Frap1/ T cells were
mock stimulated or stimulated with TGF-b and examined by
immunoblot for Smad3 activation. At baseline, the mTOR-defi-
cient T cells displayed robust phosphorylation of Smad3 and
this phosphorylation increased with the addition of TGF-b (Fig-
ure 6B). In contrast, the levels of Smad3 phosphorylation in the
WT T cells were very low and they increased modestly upon
stimulation with this dose of TGF-b.840 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.TGF-b is a potent stimulus for Smad3 activation. However, we
knew that there was not excessive TGF-b produced in the
cultured cells from T-Frap1/ mice. Thus, we wanted to deter-
mine whether the little TGF-b that was present in these cultures
was driving differentiation to regulatory T cells. Wild-type and
T-Frap1/ cells were stimulated overnight in the presence or
absence of TGF-b-neutralizing antibodies. Cells were washed
the next day and rested in IL-7 as well as additional neutralizing
antibodies. After a 5 day rest, the cells were examined for Treg
cell markers. Although 23.6% of the untreated T-Frap1/
T cells were Foxp3+, CD4 cells, the addition of neutralizing anti-
bodies to TGF-b reduced the generation of Foxp3+ cells to
14.2% (Figure 6C). These observations suggest that the TGF-b
produced in anormally activating inflammatorymilieu contributes
to the induction of Foxp3+ regulatory cells in the absence of
mTOR activation.
TORC1-Deficient T Cells Fail to Become Regulatory
T Cells
Rapamycin is believed to directly affect the TORC1 signaling
complex. Because rapamycin promotes the generation of regu-
latory T cells in vitro, the ablation of TORC1 should yield regula-
tory T cell differentiation. However, it is becoming increasingly
apparent that rapamycin can also affect the assembly and
signaling of TORC2 (depending on cell type and length of expo-
sure) (Sabatini, 2006). Because mTOR-deficient T cells delete
both TORC1 and TORC2 signaling, we sought to create a mouse
whereby TORC1 signaling was selectively inhibited in T cells.
Rheb is a critical positive regulator of mTORC1 signaling
(Avruch et al., 2006). Therefore we bred Rheb floxed mice (B.X.
and P.F.W., unpublished data) to CD4-Cre mice to generate
a conditionalRheb deletion in T cells (Rhebfl/fl; CD4-Cre, referred
to as T-Rheb/). Similar to the T-Frap1/mice, we detected no
difference in T cell subsets in the lymph node, spleen, and blood
(data not shown; the full characterization of the T-Rheb/ mice
will be reported in a separate manuscript). Also, thymic develop-
ment was normal and no differences in the CD4:CD8 ratio was
detected (data not shown). T cells from WT and T-Rheb/
mice were stimulated with anti-CD3 and anti-CD28 in vitro and
interrogated for phospho-S6K1 (TORC1 activation) and phos-
pho-Akt (serine 473) (TORC2 activation) (Figure 6D). Upon stimu-
lation, the T-Rheb/ T cells failed to phosphorylate S6K1.
However, there was intact (and slightly elevated) TORC2 activity
as determined by Akt phosphorylation of serine 473. These
observations are consistent with the ability of TORC1 to inhibit
TORC2 signaling through a negative feedback loop.
T cells from wild-type, T-Rheb/, and T-Frap1/ mice were
stimulated with anti-CD3 and APCs for 24 hr and rested in IL-7-
supplemented media for 5 days. The cells were then harvested
and analyzed by flow cytometry. As expected, the WT T cells
failed to differentiate into regulatory cells and the T-Frap1/
cells were induced to express Foxp3 (Figure 6E). However, in
spite of the fact that the T-Rheb/ cells lack TORC1 activation,
they failed to induce Foxp3. Recent studies have shown that
T cells expressing a constitutively active Akt failed to upregulate
Foxp3 (Haxhinasto et al., 2008). Because the T-Rheb/ cells
demonstrated slightly elevated Akt activation, we determined
whether these cells were capable of becoming Foxp3+ cells.
Naive wild-type and T-Rheb/ T cells were activated in the
Immunity
mTOR Regulates Effector T Cell Lineage CommitmentFigure 6. TORC1-Deficient T Cells Fail to Become Regulatory T Cells
(A) TGF-b production in splenocytes from WT and mTOR-deficient T cell cultures as measured by ELISA. Data are pooled from seven experiments. Error bars
indicate SD.
(B) mTOR-deficient cells have hyperphosphorylated Smad3. Previously activated cells were stimulated with TGF-b (5 ng/mL) for 30 min and probed (IB) for phos-
pho-Smad3.
(C) TGF-b is important for mTOR-deficiency-mediated Treg cell induction. Cells were stimulated as in Figure 5A in the presence or absence of TGF-b-neutralizing
antibodies.
(D) Rheb deficiency selectively inhibits TORC1 activity. Previously activated T-Rheb/ T cells were stimulated in vitro with anti-CD3 and anti-CD28 for the indi-
cated times and probed for mTOR substrates by IB. Pan Akt is included as a loading control.
(E) Rheb-deficient T cells do not spontaneously convert into Treg cells. WT, T-Rheb/, and T-Frap1/ cells were stimulated with anti-CD3 and APCs and rested
in IL-7-supplemented media for 5 days and interrogated for Treg cell markers.
(F) Rheb-deficient T cells can be skewed to Treg cells. WT and T-Rheb/ cells were stimulated in the presence or absence of Treg cell skewing conditions and
analyzed after 5 days. Cells were then interrogated for Treg cell markers by flow cytometry. All data are representative of at least three independent experiments.Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc. 841presence or absence of TGF-b. After 5 days, the cells were
examined for Treg cell markers. In the presence of TGF-b, the
T-Rheb/ cells were induced to express Foxp3 (Figure 6F).Thus, even though T-Rheb/ cells failed to become Treg cells
under activating conditions, they differentiated into inducible
Treg cells when activated in the presence of TGF-b.
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There is much plasticity with regard to the development of
distinct T effector or regulatory cell lineages upon antigen recog-
nition (Weaver et al., 2006). In addition to Th1 or Th2 cell type
CD4+ T cells, a third effector subset of T cells termed Th17 cells
can be produced through the presence of TGF-b and IL-6.
However, stimulation in the presence of TGF-b without IL-6
causes CD4+CD25 T cells to develop into Foxp3+ regulatory
cells. Our data demonstrate that by regulating cytokine signals
and the subsequent expression of lineage-specific transcription
factors, mTOR is important in determining antigen-induced fate
with regard to the development of effector versus regulatory
T cells. That is, mTOR activation is essential for the development
of effector T cell lineage commitment. Under strongly activating
skewing conditions for Th1, Th2, and Th17 cell development, in
the absence of mTOR, T cells differentiated down a regulatory
pathway. Thus, our data support a paradigmwhereby the default
pathway for TCR engagement is toward regulatory cells, and that
accessory signals leading to the activation of mTOR are required
to redirect antigen recognition toward active immunity.
In yeast and other primitive eukaryotic cells, TOR senses the
environment and instructs cellular processes (Hay and Sonen-
berg, 2004). In an environment lacking amino acids, energy,
and nutrients, TOR is inhibited and protein synthesis curtailed.
By analogy, our data suggest an important role for mTOR in
integrating environmental cues in the form of cytokine stimula-
tion. In the absence of mTOR, cytokines such as IL-12, IFN-g,
and IL-4 failed to promote the upregulation of lineage-specific
transcription factors, in part because of a decrease in appro-
priate STAT activation. In this fashion our data revealed a role
for mTOR in facilitating STAT activation in response to cytokines
in lymphocytes. This was particularly so in the case of IL-6-
induced STAT3 activation, which was markedly absent in the
mTOR-deficient T cells. At this time it is unclear whether mTOR
plays a direct role in STAT phosphorylation. However, our find-
ings are consistent with recent observations in tumor cells and
in IL-6-induced insulin resistance implicating a role for mTOR
in STAT3 activation (Kim et al., 2008; Zhou et al., 2007). Thus,
mTOR plays the simultaneous role of inducing specific effector
differentiation by promoting STAT activation and inhibiting
Smad3 phosphorylation.
Although mTOR-deficient T cells had decreased responses to
IL-12, IFN-g, IL-4, and IL-6, interestingly, exogenous IL-2
hastened the development of Foxp3+ T cells from the mTOR-
deficient cultures. IL-2 was first identified as ‘‘T cell growth
factor’’ and in fact IL-2 receptor signaling leads to mTOR activa-
tion (Abraham and Wiederrecht, 1996). However, recent data
clearly demonstrate an important role for IL-2 in maintaining
tolerance (Lohr et al., 2006). Both IL-2 and IL-2 receptor null
mice seem paradoxically to have autoimmune phenotypes
(Sadlack et al., 1995). It is believed that the increased autoimmu-
nity in these mice is due the critical role that IL-2 plays in
promoting the generation of regulatory T cells. In this context,
our data serve to dissect IL-2R signaling into mTOR-dependent
(activating) and mTOR-independent (regulatory) pathways.
Upstream of mTOR, a signaling cascade from PI3K-Akt leads
to the inactivation of TSC2 and subsequently the activation of
mTOR. Downstream, mTOR signaling occurs via two distinct842 Immunity 30, 832–844, June 19, 2009 ª2009 Elsevier Inc.complexes, mTORC1 and mTORC2. Haxhinasto et al. (2008)
have been able to link Akt activation and the regulation of
Foxp3. In this work, the forced overexpression of a constitutively
active Akt led to a decrease in expression of Foxp3 target genes.
The addition of rapamycin abrogated this affect and it was
concluded that Akt was acting upstream of mTOR. Likewise,
based on observations from PTEN null cells and pharmacologic
inhibitors of PI3-kinase, Akt, and mTOR, Sauer et al. (2008)
propose that the PI-3K-Akt-mTOR axis negatively regulates
Foxp3 expression. Our data employing Rheb null T cells (in which
TORC1 is selectively eliminated) shed new light on this pathway
and reveal a heretofore unappreciated role for TORC2 in regu-
lating Foxp3 expression. Our data support a model whereby
mTOR signaling via TORC2-induced activation of Akt plays
a role in negatively regulating Foxp3 expression as opposed to
Akt inhibiting Foxp3 expression through the exclusive activation
of TORC1. Notably, TORC2 inhibition appears to be necessary
for the upregulation of Foxp3; however, it is unclear whether it
is sufficient.
Although the generation of inducible regulatory T cells has
been shown in the context of suboptimal TCR engagement, inad-
equate costimulation, and exogenous TGF-b, in our system regu-
latory T cells are generated despite strong TCR engagement, full
costimulation, and in the absence of exogenous TGF-b (Chen
et al., 2003; Kretschmer et al., 2005). Although a similar low level
of TGF-b production was observed for both WT and T-Frap1/
T cells, our data support an increased sensitivity of mTOR-defi-
cient cells to such modest TGF-b stimulation. First, the addition
of neutralizing antibodies to TGF-b diminished the generation of
regulatory T cells. Second, Smad3, a downstream component
of TGF-b signaling that is involved in Foxp3 transcription, is
hyperactive in the mTOR-deficient T cells. It has been previously
shown that Akt activation can inhibit TGF-b-mediated phosphor-
ylation of Smad3 (Song et al., 2006). Thus, mechanistically, we
propose that in the absence of mTOR, TORC2-mediated activa-
tion of Akt is absent, resulting in hyperphosphorylation of Smad3.
Taken as a whole, we propose that in the inflammatory milieu,
T cells receive multiple and opposing environmental cues and
that the resulting amount of mTOR activation influences the
outcome of antigen recognition. For example, in the setting of
an inflammatory response without concurrent mTOR activation,
even small amounts of TGF-b would lead to regulatory T cell
lineage commitment. Recently, it has been shown that TGF-b
can antagonize RORgt function and thus promote regulatory
T cell development over Th17 effector cell differentiation (Zhou
et al., 2008). Our data suggest that this balance between effector
and regulatory lineage commitment extends to all effector cells
(not just Th17 cells) and is controlled, at least in part, by mTOR.
As a result of the critical role of mTOR in development, mTOR
null mice are early embryonic lethal (Gangloff et al., 2004).
Because in our model mTOR is deleted relatively late in T cell
development (at the double-positive stage), our data do not
address the role ofmTOR inearlier aspects of T cell development.
Nonetheless, in light of the important role of mTOR in multiple
cellular functions, itwas somewhat surprising that itwasdispens-
able for T cell homeostasis and proliferation. Such findings
suggest that the function of mTOR is more important under
conditions of activation or stress. mTOR-independent pathways
must regulatemetabolism, survival, and proliferation during T cell
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explain this is expression of Pim kinases that have been shown
to regulate T cell activation and survival throughmTOR-indepen-
dent pathways (Fox et al., 2005). Along these lines it has been
proposed that Pim2 kinase is a Foxp3 target gene and thus upre-
gulated in regulatory T cells (Basu et al., 2008). Such alternative
pathways provide a potential explanation for the ‘‘lack of’’ effect
of mTOR deletion on T cell homeostasis and survival. Likewise,
naive T cells do not require mTOR for initial TCR-mediated cyto-
kine production. However, such antigen recognition in the
absence of mTOR induces a subsequent genetic program that
prevents effector T cell differentiation and promotes adaptive
regulatory T cell lineage commitment.
Finally, our genetic approach unequivocally identifies mTOR
and its downstream effectors as potential pharmacologic targets
for the prevention of effector T cell development and promoting
tolerance. Previously, we have been able to demonstrate the
ability of rapamycin but not cyclosporine A (which inhibits TCR
signaling) to promote long-term bone marrow chimerism in the
absence of long-term immunosuppression (Powell et al., 2005).
Along these lines recently it has been shown that both cyclo-
sporine A and rapamycin inhibit IL-17 production in vitro but
cyclosporine A inhibits whereas rapamycin promotes the gener-
ation of regulatory T cells (Kopf et al., 2007). Given the role of
mTOR in promoting T effector generation, we propose that
optimal immunosuppressive regimens would allow for TCR
engagement,while simultaneously inhibiting cytokine production
(e.g., costimulatory blockade) and inhibiting mTOR activation.
EXPERIMENTAL PROCEDURES
Mice
All mouse work was done in accordance with the Animal Care and Use
Committee guidelines for Johns Hopkins University. Animals were housed in
pathogen-free conditions prior tomanipulations.Frap1fl/flmicewere generated
in the lab of S.C. Kozma and G. Thomas by selecting the original mTORneo ES
cell clone (Gangloff et al., 2004) for loss of the neo cassette after transient trans-
fection with a Cre-expressing plasmid. The floxed Frap1 (Frap1fl/fl) mouse line
was bred to B10.D2 mice carrying a CD4-Cre transgene and a TCR transgene
specific for HA peptide (clone 6.5) (a gift from C. Drake, Johns Hopkins Univer-
sity, Baltimore, MD). Genotyping on tail DNA was performed as previously
described (Safford et al., 2005). An amplification of 500 bp by primers AC11
(50-TTCATTCCCTTGAAAGCCAGTCTCACC) and AC14 (50-TCATTACCTTCT
CATCAGCCAGCAGTT) indicates the presence of a floxed Frap1 allele. An
amplification of 250 bp indicates a WT Frap1 allele. Amplification of primers
AC11 and AC16 (50-TTCATTCCCTTGAAAGCCAGTCTCACC) 550 bp indi-
cates an excised Frap1 gene (as in Figure 1A). PCR was used to genotype
tail DNA for the presence of CD4-Cre (forward 50-CGATGCAACGAGTGATG
AGG, reverse 50-CGCATAACCAGTGAAACAGC). Rhebfl/fl mice were gener-
ated by P.F. Worley (B.X. and P.F.W., unpublished data). Genotyping on tail
DNA was performed with primers RF1 (50- GCCCAGAACATCTGTTCCAT)
and RR1 (50- GGTACCCACAACCTGACACC). 653 bp indicates a wild-type
allele whereas 850 bp indicates a floxed allele.
Flow Cytometry
All plots shown are on populations that were gated on lymphocytes by forward
and side scatter. All antibodies (except Foxp3) for FACS were purchased from
BD Biosciences. The antibody and staining kit for Foxp3 was purchased from
eBioscience (Foxp3-FITC, FJK-16 s) (San Diego, CA).
Cell Isolations
CD4+ T cells were isolated with the MACS CD4+ T cell Isolation Kit (Miltenyi
Biotec, Auburn, CA), according to the manufacturer’s instructions. All isola-tions were performed with LS columns or the autoMACS cell separator. Where
indicated, cells were labeled with CFSE in suspension at 10 3 106/mL with
5 mM CFSE (BD Bioscience) for 15 min. The reaction was quenched with 2%
FBS in PBS.
Cell Stimulations
Cells were stimulated with anti-CD3 (2C11, BD Biosciences) and HA class II
peptide (Peptide Core Facility, Johns Hopkins University) as indicated.
Antigen-presenting cells were generated by isolating splenocytes from
B10.D2 (syngeneic) mice. T cell depletion was performed by staining with
anti-CD3-biotin and anti-biotin microbeads (MACS separation) (Miltenyi Bio-
tec), according to the manufacturer’s instructions. Cells used as APCs were
irradiated with 3000 rads in compliance with Radiation Safety at Johns Hop-
kins University. Cells skewed to Th1 cell conditions were cultured in media
supplemented with mIL-12 (10 ng/ml, Peprotech) and anti-IL-4 (10 mg/mL,
11B11, NCI-Frederick Repository), with additional IL-2-supplemented media
being added after 48 hr. Cells skewed to Th2 were supplemented with mIL-4
(10 ng/ml, Peprotech), anti-IL-12 (10 mg/ml, Invitrogen), and anti-IFN-g
(10 mg/ml, XMG1.2, a gift fromD. Pardoll, Johns Hopkins University), with addi-
tional IL-2 supplementation added after 48 hr. Cells skewed to Th17 were sup-
plemented with TGF-b (10 ng/ml) and mIL-6 (10 ng/ml) (Peprotech). Th17 cells
were also isolated from Peyer’s patches by manual dissection, straining cells
through a cell strainer, and stimulating all cells with PMA and ionomycin in the
presence of GolgiStop.
Real-Time PCR
Real-time PCR was performed essentially as described (Safford et al., 2005).
Real-time PCR used primers and probes obtained from Applied Biosystems
(Foster City, CA) specific for T-bet (Tbx21, Mm00450960_m1), GATA-3
(Mm00484683_m1), IL-21 (Mm00517640_m1), and IL-23R (Mm00519942_m1).
RORgt was probed as previously described (Harris et al., 2007).
Immunoblotting
Immunoblots were performed essentially as described (Safford et al., 2005).
Primary antibodies were used against mTOR, phospho-S6K1(p70S6K) (T421/
S424), pan S6K1 (p70S6K), phospho-Akt (T308), phospho-STAT3 (Y705),
phospho-STAT6 (Y641), pan STAT3, pan STAT6 phospho-Smad3 (S423/
S425) (Cell Signaling Technology, Danvers, MA), AKT1/2, pan Smad3, cyclin
D3 (Santa Cruz, Santa Cruz, CA), phospho-Akt (S473) (Upstate, Chicago, IL),
phospho-STAT4 (Y693), and pan STAT4 (Abcam, Cambridge, MA).
Detection of Cytokines
Supernatants were removed and diluted for cytokine detection. Cytokines
were detected with ELISA kits from eBioscience (IL-2, IL-4, IFN-g, TGF-b)
according to the manufacturer’s instructions.
In Vitro Suppression
CD4+CD25+ cells were isolated from enriched CD4+ 5-day T-Frap1/ cultures
by CD25+ positive selection (Miltenyi Biotec). Naive 6.5+ T cells were isolated
from splenocytes with the CD4+ T cell isolation kit (negative selection) (Miltenyi
Biotec) and CFSE labeled. T cell depleted, irradiated, syngeneic splenocytes
were used as APCs to present HA peptide. Responder cells were interrogated
for proliferation by FACS analysis via differential Thy expression.
Adoptive Transfers
Host mice (B10.D2, Thy1.2) were injected i.p. with 13 106 PFU Vac-HA (a gift
from C. Drake, Johns Hopkins University). 2 3 106 WT or mTOR-deficient
CD4+ T cells were injected i.v. 1 day after immunization. Splenocytes were
harvested 5 days after transfer and subjected to ex vivo rechallenge with HA
peptide (100 mg/mL) in the presence of GolgiStop (BD Biosciences). 6 hr after
stimulation, cells were harvested and stained with the BDBiosciences Cytofix/
Cytoperm kit.
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